Immunovant Q4 2020 Earnings Report

Reported financial results for the quarter and fiscal year ended March 31, 2020, and announced plans for Phase 3 registrational trial of IMVT-1401 in Myasthenia Gravis.

Key Takeaways

Immunovant reported its financial results for the fiscal fourth quarter and fiscal year ended March 31, 2020. The company's cash balance as of June 29, 2020, is approximately $280.4 million. They've begun preparations to initiate a Phase 3 registrational trial of IMVT-1401 in MG.

Initiated preparations for a Phase 3 registrational trial of IMVT-1401 in Myasthenia Gravis (MG).

IMVT-1401's development program is based on a subcutaneous injection format.

Cash balance as of June 29, 2020, is approximately $280.4 million.

Announced positive clinical results from ASCEND GO-1, a Phase 2a trial of IMVT-1401 in Thyroid Eye Disease (TED).